Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1983 1
1984 2
1985 1
1986 2
1988 1
1989 2
1990 1
1991 1
1992 3
1993 2
1994 3
1995 3
1996 3
1997 2
1998 4
1999 2
2000 4
2001 1
2002 4
2003 4
2004 2
2005 1
2006 3
2007 1
2008 4
2009 3
2010 3
2011 6
2012 3
2013 4
2014 5
2015 7
2016 4
2017 2
2018 2
2019 2
2020 2
2021 1
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Severe Aplastic Anemia"
Page 1
Temozolomide-related hematologic toxicity.
Scaringi C, De Sanctis V, Minniti G, Enrici RM. Scaringi C, et al. Onkologie. 2013;36(7-8):444-9. doi: 10.1159/000353752. Epub 2013 Jul 8. Onkologie. 2013. PMID: 23921765 Review.
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit. ...The most common side effects are mild to moderate, and are represented by fatigue, nausea, vomiting, thrombocytopen …
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with signific …
Anti-thymocyte globulin in haematology: Recent developments.
Siddiqui S, Cox J, Herzig R, Palaniyandi S, Hildebrandt GC, Munker R. Siddiqui S, et al. Indian J Med Res. 2019 Sep;150(3):221-227. doi: 10.4103/ijmr.IJMR_752_19. Indian J Med Res. 2019. PMID: 31719292 Free PMC article. Review.
It induces a broad non-specific immunosuppression. In haematology, standard indications are severe aplastic anaemia and prophylaxis and treatment of graft-versus-host disease (GVHD) (after allogeneic transplantation). For aplastic anaemia, ATG f …
It induces a broad non-specific immunosuppression. In haematology, standard indications are severe aplastic anaemia and …
Acquired aplastic anemia following SARS-CoV-2 vaccination.
Röth A, Bertram S, Schroeder T, Haverkamp T, Voigt S, Holtkamp C, Klump H, Wörmann B, Reinhardt HC, Alashkar F. Röth A, et al. Eur J Haematol. 2022 Aug;109(2):186-194. doi: 10.1111/ejh.13788. Epub 2022 Jun 1. Eur J Haematol. 2022. PMID: 35592930 Free PMC article.
COVID-19 is a potential life-threatening viral disease caused by SARS-CoV-2 and was declared a pandemic by the WHO in March 2020. mRNA-based SARS-CoV-2 vaccines are routinely recommended in immune-compromised patients, including patients with AA, as these patients are at increase …
COVID-19 is a potential life-threatening viral disease caused by SARS-CoV-2 and was declared a pandemic by the WHO in March 2020. mRNA-based …
Management of aplastic anemia after failure of frontline immunosuppression.
Pierri F, Dufour C. Pierri F, et al. Expert Rev Hematol. 2019 Oct;12(10):809-819. doi: 10.1080/17474086.2019.1645003. Epub 2019 Jul 24. Expert Rev Hematol. 2019. PMID: 31311355 Review.
Introduction: About 60% of aplastic anemia (AA) patients are in need of further treatment after frontline standard immunosuppressive therapy (IST). ...Areas covered: Literature research, carried out from the most commonly used databases, included the following keywo …
Introduction: About 60% of aplastic anemia (AA) patients are in need of further treatment after frontline standard immunosuppr …
Prognostic value of telomere attrition in patients with aplastic anemia.
Scheinberg P. Scheinberg P. Int J Hematol. 2013 May;97(5):553-7. doi: 10.1007/s12185-013-1332-x. Epub 2013 May 1. Int J Hematol. 2013. PMID: 23636667 Review.
The decision to pursue hematopoietic stem cell transplantation or immunosuppression as first therapy in severe aplastic anemia is currently based on age and availability of a histocompatible donor. ...This review will summarize studies in marrow failure that …
The decision to pursue hematopoietic stem cell transplantation or immunosuppression as first therapy in severe aplastic ane …
High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.
Gamper CJ, Takemoto CM, Chen AR, Symons HJ, Loeb DM, Casella JF, Dezern AE, King KE, McGonigle AM, Jones RJ, Brodsky RA. Gamper CJ, et al. J Pediatr Hematol Oncol. 2016 Nov;38(8):627-635. doi: 10.1097/MPH.0000000000000647. J Pediatr Hematol Oncol. 2016. PMID: 27467367 Free PMC article.
OBJECTIVE: Use of high-dose cyclophosphamide without hematopoietic stem cell transplant to treat severe aplastic anemia (SAA) has been controversial due to concern for increased infectious toxicity as compared with antithymocyte globulin and cyclosporine A. A …
OBJECTIVE: Use of high-dose cyclophosphamide without hematopoietic stem cell transplant to treat severe aplastic anemia …
Recent Advances and Long-Term Results of Medical Treatment of Acquired Aplastic Anemia: Are Patients Cured?
Scheinberg P. Scheinberg P. Hematol Oncol Clin North Am. 2018 Aug;32(4):609-618. doi: 10.1016/j.hoc.2018.03.003. Epub 2018 May 18. Hematol Oncol Clin North Am. 2018. PMID: 30047414 Review.
Horse antithymocyte globulin plus cyclosporine remains standard immunosuppressive therapy in severe aplastic anemia, with hematologic response rates of 60% to 70%. In those refractory to this regimen, a second course of therapy with rabbit antithymocyt …
Horse antithymocyte globulin plus cyclosporine remains standard immunosuppressive therapy in severe aplastic anemia, wi …
Allogeneic bone marrow transplantation.
Weiden PL. Weiden PL. Crit Rev Clin Lab Sci. 1983;19(3):173-86. doi: 10.3109/10408368309165762. Crit Rev Clin Lab Sci. 1983. PMID: 6373140 Review.
Allogeneic bone marrow transplantation now has an established place in the treatment of severe aplastic anemia and acute leukemia. Major problems to be overcome in transplantation in patients with aplastic anemia are marrow graft rejection and g …
Allogeneic bone marrow transplantation now has an established place in the treatment of severe aplastic anemia and acut …
Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.
Dale DC, Bolyard AA, Shannon JA, Connelly JA, Link DC, Bonilla MA, Newburger PE. Dale DC, et al. Blood Adv. 2022 Jul 12;6(13):3861-3869. doi: 10.1182/bloodadvances.2021005684. Blood Adv. 2022. PMID: 35476051 Free PMC article.
Severe chronic neutropenia (SCN), defined as blood neutrophils <0.5 109/L for >3 months, is an uncommon hematological condition associated with recurrent and severe bacterial infections. ...Progression to systemic autoimmune diseases, bone marrow (BM) f …
Severe chronic neutropenia (SCN), defined as blood neutrophils <0.5 109/L for >3 months, is an uncommon hematological condition …
Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.
Scheinberg P, Townsley D, Dumitriu B, Scheinberg P, Weinstein B, Daphtary M, Rios O, Wu CO, Young NS. Scheinberg P, et al. Blood. 2014 Oct 30;124(18):2820-3. doi: 10.1182/blood-2014-05-573642. Epub 2014 Sep 3. Blood. 2014. PMID: 25185712 Free PMC article. Clinical Trial.
First-line therapy of severe aplastic anemia (SAA) with high-dose cyclophosphamide causes toxicity and increased short-term mortality. We investigated cyclophosphamide at a lower, more moderate dose in combination with aggressive supportive care to determine …
First-line therapy of severe aplastic anemia (SAA) with high-dose cyclophosphamide causes toxicity and increased short- …
99 results